Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processes

• Published in: Life sciences (1973) 2024-04, Vol.342, p.122537-122537, Article 122537
• Main Authors: Dhiman, Sonia, Mannan, Ashi, Taneja, Ayushi, Mohan, Maneesh, Singh, Thakur Gurjeet
• Format: Article
• Language: English
• Subjects: Acetylation; Deacetylation; Mitochondrial dysfunction; Neuroinflammation; Oxidative stress; Parkinson's disease; Protein aggregation; Sirtuins
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2024.122537

Parkinson's disease (PD) is a progressive neurodegenerative condition that primarily affects motor function and is caused by a gradual decline of dopaminergic neurons in the brain's substantia pars compacta (Snpc) region. Multiple molecular pathways are involved in the pathogenesis, which results in impaired cellular functions and neuronal degeneration. However, the role of sirtuins, a type of NAD+-dependent deacetylase, in the pathogenesis of Parkinson's disease has recently been investigated. Sirtuins are essential for preserving cellular homeostasis because they control a number of biological processes, such as metabolism, apoptosis, and DNA repair. This review shed lights on the dysregulation of sirtuin activity in PD, highlighting the role that acetylation and deacetylation processes play in the development of the disease. Key regulators of protein acetylation, sirtuins have been found to be involved in the aberrant acetylation of vital substrates linked to PD pathology when their balance is out of balance. The hallmark characteristics of PD such as neuroinflammation, oxidative stress, and mitochondrial dysfunction have all been linked to the dysregulation of sirtuin expression and activity. Furthermore, we have also explored how the modulators of sirtuins can be a promising therapeutic intervention in the treatment of PD. [Display omitted]